Thus, it is possible that the variations in metformin pharmacokinetics, which depend on the pregnancy status of the woman, can contribute to the observed low success rates of this molecule in treating GDM (46% of women in the MIG trial received supplemental insulin therapy as add-on to metformin) [109]. The gene discussed is INS; the disease is gestational diabetes.